Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trial to assess safety, efficacy, tolerability and immunogenicity of influenza virus vaccine, administered concomitantly with a combination live, attenuated, mumps, measles, and rubella vaccine in healthy children aged 11-24 months

Trial Profile

Trial to assess safety, efficacy, tolerability and immunogenicity of influenza virus vaccine, administered concomitantly with a combination live, attenuated, mumps, measles, and rubella vaccine in healthy children aged 11-24 months

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2010

At a glance

  • Drugs Influenza virus vaccine live; Measles mumps and rubella virus vaccine
  • Indications Influenza virus infections; Measles; Mumps; Rubella
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Jan 2010 Results have been published in the journal Vaccine.
    • 01 Jan 2010 Primary endpoint 'Seroconversion rate' has not been met.
    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top